Allied renews hostilities with US rival
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Allied Colloids, the chemicals group on the end of a pounds 1.1bn hostile bid from Hercules, launched another attack on its US rival yesterday as the war of words between the two sides escalated.
Allied branded Hercules criticisms of its performance as misleading and spurious. It also said the number of acceptances that Hercules had received, currently 0.94 per cent of Allied's shares, was minimal.
David Farrar, Allied's chief executive, said: "Hercules has had to grasp at straws and has had to use thoroughly misleading arguments. Shareholders should reject its rhetoric and its offer."
Mr Farrar added that the group was determined to remain independent and that is was not looking at the moment for a "white knight" to protect itself from Hercules. A spokesman for Hercules retorted: "Today's statement has barely addressed the serious questions and concerns we have raised. Once again Allied Colloids has not added any substance to the debate."
Sources suggested Hercules was considering raising its offer to provide a knock-out blow. However, the group is unlikely to raise its bid before Allied produces its final defence document on 4 January.
Allied dismissed suggestions that the acquisition of CPS, a US chemicals group, would dilute earnings and that it was massaging profits at its core business by transferring sales from CPS. Allied is visiting its large institutional shareholders in an attempt to get them to hold on to their holdings.
Allied's shares remained unchanged at 165p.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments